Abstract

Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin receptor intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons

Abstract

Disclosed herein are aspects of compounds according to Formula I and Formula II. Also disclosed are pharmaceutical compositions comprising the compounds and method for making and using the compounds. The compounds are useful as autophagy modulators. Additionally, the disclosed compounds may be useful as therapeutics for treating and/or preventing neurodegenerative diseases including Alzheimer's disease.

IPC Classes  ?

• C07D 471/10 - Spiro-condensed systems
• A61P 25/00 - Drugs for disorders of the nervous system
• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

N-Lactoyl-Phenylalanine (Lac-Phe) analogues are disclosed having activity as appetite suppressants useful as therapeutics in the treatment of obesity and related secondary diseases. Methods of synthesis of the N-Lactoyl-Phenylalanine (Lac-Phe) analogues are also disclosed, as well as methods of use and treatment with the Lac-Phe analogues.

Abstract

The invention features methods of treating multiple sclerosis in subjects having reactivated Epstein-Barr virus by administration of brincidofovir.

IPC Classes  ?

• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/12 - Antivirals

Abstract

A bioreactor vessel platform for submersion in a bioreactor vessel or petri dish may have different versions for initial and later stage development of cell cultures. The initial stage platform can include a center platform hub and an outer circumferential rim creating a central reservoir and a plurality of culture reservoirs. A magnetic stir bar can be rotated in the central reservoir to direct oxygenated culture medium to cell cultures in the culture reservoirs. The second stage platform has a multi-well configuration with a plurality of culture wells separated by distribution channels and may be made of a porous hydrogel.

IPC Classes  ?

• C12M 1/22 - Petri dishes
• C12M 1/32 - Inoculator or sampler multiple field or continuous type
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

The invention provides scaffold compounds having anti-hRPN13 activity and pharmaceutical compositions comprising the same. The invention also provides methods of treating a disease, such as cancer, in a subject, comprising administering the scaffold compounds and pharmaceutical compositions described herein.

IPC Classes  ?

• C07D 209/34 - Oxygen atoms in position 2
• C07C 255/00 - Carboxylic acid nitriles
• C07F 5/02 - Boron compounds
• C07D 231/36 - Oxygen atoms with hydrocarbon radicals, substituted by hetero atoms, attached in position 4
• C07D 277/34 - Oxygen atoms
• C07D 279/16 - 1,4-ThiazinesHydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 35/00 - Antineoplastic agents
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

Determining predicted torque values for a powered gait assistance system are described. The method comprises: obtaining a training dataset comprising training sensor data associated with measurements of a plurality of first individuals using one or more first powered gait assistance systems; training a multilayer perceptron (MLP) using the training sensor data; obtaining, from one or more sensors of a powered gait assistance system, sensor data associated with a second individual using the powered gait assistance system; processing the sensor data associated with the second individual using the trained MLP to generate predicted torque values for a second powered gait assistance system; and applying the predicted torque values to a motor of the second powered gait assistance system to cause the motor to apply assistive torque, that corresponds to the predicted torque values, between the first and second arms of the second powered gait assistance system.

IPC Classes  ?

• A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
• A61H 3/00 - Appliances for aiding patients or disabled persons to walk about

Abstract

Provided herein are engineered protein comprising stabilized coronavirus S protein ectodomains, such as stabilized SARS-CoV-2 S2 domain-only ectodomains that exhibit improved conformational homogeneity and biophysical stability. The ectodomains are incorporated into nanoparticles. Methods are also provided for use of the stabilized coronavirus S protein ectodomains and/or nanoparticles as diagnostics, in screening platforms, and/or in vaccine compositions.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A method is provided for non-invasively predicting characteristics of one or more cells and cell derivatives. The method includes training a machine learning model using at least one of a plurality of training cell images representing a plurality of cells and data identifying characteristics for the plurality of cells. The method further includes receiving at least one test cell image representing at least one test cell being evaluated, the at least one test cell image being acquired noninvasively and based on absorbance as an absolute measure of light, and providing the at least one test cell image to the trained machine learning model. Using machine learning based on the trained machine learning model, characteristics of the at least one test cell are predicted. The method further includes generating, by the trained machine learning model, release criteria for clinical preparations of cells based on the predicted characteristics of the at least one test cell.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06F 18/214 - Generating training patternsBootstrap methods, e.g. bagging or boosting
• G06T 7/00 - Image analysis
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

Disclosed are live-attenuated human parainfluenza virus (HPIV) immunogenic molecules comprising at least one codon-pair deoptimization (CPD) in an open reading frame (ORF) of a HPIV gene that encodes at least one HPIV protein. In addition, pharmaceutical compositions comprising the immunogenic molecules, methods and kits for using the immunogenic molecules and pharmaceutical compositions, and methods of making the immunogenic molecules are disclosed, in accordance with aspects of the invention.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Disclosed herein is a modified transposase, comprising a core piggy Bac transposase having one or more modifications making it capable of excising and integrating a piggy Bac transposon in LE/LE configuration leading to hyperactivity. Also disclosed is a modified piggy Bac transposase capable of excising but not integrating a piggy Bac transposon in LE/LE configuration. Also disclosed herein is a modification of the mammalian Myotis lucifugus DNA transposon involving modification both its transposase and transposon LE and RE ends by truncations leading to hyperactivity.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Polynucleotide expression cassettes comprising synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) are described herein. Related recombinant expression vectors, recombinant adeno-associated viruses (rAAVs), and compositions are also described. Also described are methods of treating a disease or condition mediated by propionyl-CoA carboxylase, comprising administering to a subject in need thereof a therapeutic amount of any of the polynucleotide expression cassettes, recombinant expression vectors, rAAVs, or compositions.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/00 - Drugs for disorders of the metabolism
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Polyfluorinated thalidomide analogs have a structure according to formula I, wherein R is aliphatic. The compounds may be used to inhibit cancer cell proliferation and/or to treat subjects with cancer or an inflammatory process. In some aspects, the cancer is multiple myeloma. In certain aspects, the compounds are used to inhibit proliferation of drug-resistant multiple myeloma cells and/or to treat subjects with drug-resistant multiple myeloma.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

In some instances, a system for rapid spectral unmixing using spectrally interpolated background reduction (SIBR) is provided. The system comprises a device comprising an excitation light source and a detector. The system further comprises a control system configured to: obtain a plurality of excitation spectra for a plurality of fluorophores that are used to stain a sample; determine a plurality of chosen wavelengths and a plurality of chosen light intensities for the plurality of fluorophores; obtain a first detection of the sample based on using a set of first wavelengths from the plurality of chosen wavelengths and a set of first light intensities; obtain a second detection of the sample based on using a set of second wavelengths from the plurality of chosen wavelengths and a set of second light intensities; and output a SIBR quantity.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01J 3/44 - Raman spectrometryScattering spectrometry

Abstract

An embodiment of the invention provides chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/395 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Saccharomyces
• C07K 14/725 - T-cell receptors
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Disclosed are bispecific antibodies, including dual variable domain immunoglobulins that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure relates to a rapid method for producing antibodies. The method uses OE-PCR to join templates encoding antibody domains, thereby forming a linear expression cassette encoding a fusion protein comprising the antibody domains. A self-cleaving peptide is positioned between variable domains such that translation of the linear expression cassette produces individual proteins, each comprising a light or heavy chain variable region. These individual proteins can then join to form an antibody. The disclosure also provides Methods of producing linear expression cassettes as well as methods of using such cassettes for treating individuals.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

CD276 (also known as B7H3) is highly expressed in the stroma of most solid tumors and is also frequently overexpressed by tumor cells, making CD276 an important target for anti-cancer therapy. Fully human monoclonal antibodies that bind CD276 are described. Chimeric antigen receptors (CARs) generated using the CD276 antibodies are also described. The monoclonal antibodies, CARs and other antibody conjugates can be used for the detection and treatment of CD276-positive cancers.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are compounds of formulas (I) and (II), a salt thereof, or an optical isomer thereof, wherein R1-R32B2B serotonin receptor selective antagonists, pharmaceutical compositions comprising such compounds, and methods of treating various diseases and conditions in an animal including fibrosis of the lung, skin, coronary, and liver, pulmonary arterial hypertension, valvular heart disease, pain, and cancer by the use of these compounds.

IPC Classes  ?

• C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
• C07D 471/04 - Ortho-condensed systems
• C07D 473/36 - Sulfur atom
• A61K 31/52 - Purines, e.g. adenine
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is a class of kinase inhibitors of formula (I) or formula (II). Related pharmaceutical compositions and methods of using the kinase inhibitors are also disclosed.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

The invention provides a protein or polypeptide derived from ERVMER34-1. The invention further provides a nucleic acid encoding the inventive protein or polypeptide, a vector comprising the nucleic acid, cells comprising the protein or polypeptide, nucleic acid, and/or vector, and composition, such as a pharmaceutical composition, comprising any of the foregoing. These reagents (the inventive protein or polypeptide, nucleic acid, vector, cell, or composition thereof) are useful for immunological treatment and prophylaxis of diseases, particularly cancers.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

e.ge.g., humanized monoclonal antibodies and antigen binding fragments) that specifically bind epidermal growth factor receptor variant III (EGFRvIII) and/or gene-amplified EGFR, as well as conjugates and chimeric antigen receptors (CARs) including such antibodies. Also provided are nucleic acid molecules encoding an antibody, conjugate, or CAR disclosed herein, and host cells expressing the nucleic acid molecules. Further disclosed are methods of using the disclosed compositions, for example, for treating or detecting a tumor, such as a tumor expressing EGFRvIII and/or gene-amplified EGFR.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

A shipping container for the support and shipment of a system for supporting at least one live cell includes a container and a lid configured to be removably coupled together to form a container cavity therebetween. A lower stabilization support and an upper guard are provided for supporting the system. The lower stabilization support is sized to be received within the container, and includes an upwardly opening recess configured to receive and support at least a portion of the system. The upper guard includes a lower surface that is sized to be at least partially received within an upwardly directed system cavity of the system. In this way, the lower stabilization support and upper guard are configured to securely support the system within the container cavity between the container and the lid.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

Provided herein are uses of iron chelators to treat stuttering. The iron chelators include deferiprone, deferoxamine, and deferasirox.

IPC Classes  ?

• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/426 - 1,3-Thiazoles
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid, valine, or arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Plasmodium yoeliiPlasmodium falciparumPlasmodium falciparum than AMA1 or AMA1-RON2L complex vaccination. This indicates that SBD1 directs neutralizing antibody responses to strain-transcending epitopes in AMA1 that are independent of RON2L binding. This work underscores the importance of neutralization mechanisms that are distinct from RON2 blockade. The stable single-component SBD1 immunogen elicits potent strain-transcending protection that may drive the development of next-generation vaccines for improved malaria and apicomplexan parasite control.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61P 33/06 - Antimalarials

Abstract

Disclosed are isolated PorA-PorB-RmpM-LpxL1-Nmeningitidis meningitidis and compositions including an effective amount of OMVs produced from these PorA-PorB-RmpM-LpxL1-N. meningitidisNeisseriaN. meningitidisN. gonorrhoeae. N. gonorrhoeae.

IPC Classes  ?

• A61K 39/095 - Neisseria
• A61P 31/04 - Antibacterial agents

Abstract

33 receptor modulators, inclusive of antagonists and agonists, with alleviated hERG liability and desirable pharmacokinetic properties, as well as compositions comprising, kits comprising, methods of administering, and methods of synthesizing the same.

IPC Classes  ?

• C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 25/36 - Opioid-abuse
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Abstract

Epidithiodiketopiperazine (ETP) analogs and methods of using the analogs are disclosed. The ETP analogs may have a structure according to Formula I (I), or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof, where R1is aryl or heteroaryl; R2is ‑H, aliphatic, heteroaliphatic, aryl, or heteroaryl; and R3and R4independently are aliphatic, heteroaliphatic, ‑H, –C(O)ORa, or ‑C(O)Ra. Each Ra independently is ‑H, aliphatic, or heteroaliphatic. The compounds may be used to inhibit hypoxia‑inducible factor 1 (HIF-1) activity and/or to ameliorate conditions characterized at least in part by abnormal levels of HIF‑1 activity. (I)

IPC Classes  ?

• C07D 513/08 - Bridged systems
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

An apparatus for preparing samples for cryogenic electron microscopy includes an acoustic transducer having a sample receiving area for receiving one or more liquid droplets. An acoustic signal generator is coupled to the acoustic transducer. Control circuitry is coupled to the acoustic signal generator, the control circuitry configured to cause the acoustic signal generator to generate a first acoustic signal at a first frequency for a first time period and subsequently to generate a second acoustic signal at a second frequency for a second time period.

IPC Classes  ?

• G01N 1/42 - Low-temperature sample treatment, e.g. cryofixation
• G01N 29/14 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object using acoustic emission techniques
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Disclosed herein are novel methods of treating substance use disorders, mitigating the development of substance addiction, reducing the severity of substance withdrawal symptoms, or reducing or preventing substance relapse by providing to the patient a therapeutically effective amount of a Medication Assisted Treatment agent and a selective dopamine D3 receptor antagonist/partial agonist. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of substance use disorders, including opioid use disorders.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 25/36 - Opioid-abuse

Abstract

The present disclosure provides compositions for viral gene therapy, e.g. Adeno-Associated virus-directed gene therapy, and methods of using the same for the treatment and/or prevention of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors

Abstract

Antisense oligonucleotides (ASOs) are provided which are capable of modulating splicing by preventing inclusion of an UNC13A cryptic exon into an UNC13A mature mRNA. Such ASOs may be used as a medicament, for example, to treat neurodegenerative disorders, particularly those associated with TDP-43 pathology.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

In a first aspect, the invention provides a genetic vector, such as a non-encapsulated vector, comprising a first DNA sequence encoding a polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a second DNA sequence comprising a non-copiparvovirus promoter operably linked to the first DNA sequence. In a second aspect, the invention provides an encapsulated genetic vector comprising a capsid comprising polypeptide able to form viral capsids with a CAP (capsid) protein of a copiparvovirus and a genome comprising either non-copiparvovirus DNA and can include adenoviral ITRs or copiparvovirus asymmetric terminal elements. Compositions comprising the inventive vectors, as well as methods of making such and using such, are provided as well.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

Immunogens comprising a recombinant HIV-1 Env ectodomain trimer stabilized in a prefusion closed conformation and wherein protomers of the trimer are genetically fused via peptide linkers are provided. In the recombinant HIV-1 Env ectodomain trimer, the C terminus of a first protomer in the trimer is fused to the N terminus of a second protomer in the trimer by first peptide linker, and the C terminus of the second protomer is fused to the N terminus of a third protomer in the trimer by a second peptide linker. In several aspects, the first and second peptide linkers contain N-linked glycan sequons, the glycosylation of which reduces the immunodominance of the membrane-proximal base of the trimer. In several implementations, the immunogen can be used to elicit an immune response to HIV-1 in a subject.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/12 - Viral antigens
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Apicomplexa or EuglenozoaToxoplasma gondiiToxoplasma gondiiToxoplasma gondii IFT88, SRS15A, SRS15B, and/or SRS15C, SRS26B protein or homolog or ortholog thereof, or a combination of two or more thereof. Methods of vaccinating animals using such vaccine compositions also are provided.

IPC Classes  ?

• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• A61K 35/68 - Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
• A61K 39/002 - Protozoa antigens
• A61K 39/005 - Trypanosoma antigens

Abstract

TyrosinaseBESTROPHINVMD2TyrosinaseTyrosinase gene.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

P. falciparumP. falciparumP. falciparum infection.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

HHH) phage display library panned against a stabilized S2 subunit trimer from the SARS-CoV-2 spike protein. The S2 subunit-specific antibodies, and conjugates thereof (including l phage particles expressing S2-specific single-domain antibodies), can be used for the diagnosis and treatment of a coronavirus infection.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Recombinant murine pneumonia viruses (rMPV) expressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein and their use as live-attenuated virus vaccines against SARS-CoV-2 is described. The rMPV expressing S protein are safe, immunogenic, and efficacious for protecting a subject again SARS-CoV-2 infection and disease, as demonstrated in a non-human primate model. The rMPV induce a strong systemic and mucosal antibody response against the SARS-CoV-2 S protein. Furthermore, a single dose of the live-attenuated rMPV induced strong protection against SARS-CoV-2 challenge, while two doses were fully protective.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/86 - Viral vectors
• A61P 31/14 - Antivirals for RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

synMMABsynMMABsynMMAB polynucleotides are also described. Methods of treating a disease or condition mediated by MMAB enzyme are also described.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)

Abstract

The present disclosure provides a method of treating hypoparathyroidism, such as hypoparathyroidism associated with a prior surgical procedure (e.g., a post-surgical hypoparathyroidism (PSH)), in a subject in need thereof, with a therapeutically effective amount of a compound of formula (I), in particular CLTX-305. In particular, a therapeutically effective amount of the compound of formula (I) (e.g., CLTX-305) reduces symptoms associated with hypoparathyroidism and minimizes hypercalciuria in hypoparathyroidism (e.g., PSH) subjects.

IPC Classes  ?

• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Abstract

Methods and systems are provided herein for a multichannel individualized stimulation therapy (MIST) system. In one example, a MIST system includes a device comprising a plurality of stimulation electrodes and a plurality of isolated current sources (ICS), wherein the device is reconfigurable to vary positions and dosimetry of pulses of stimuli applied to a patient.

IPC Classes  ?

• A61N 1/04 - Electrodes
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/372 - Arrangements in connection with the implantation of stimulators
• A61N 1/378 - Electrical supply

Abstract

Administration of aquaporin-1 (AQP1) complementary deoxyribonucleic acid (cDNA) to a salivary gland prior to treatment with ionizing radiation (IR) prevents the subsequent IR-induced loss in function. The administration of AQPI (e.g., human AQP1: hAQP1) prior to IR treatment (e.g., in patients with head and neck cancer) can reduce or prevent IR-induced salivary hypofunction, resulting in an elevated salivary output.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 15/86 - Viral vectors

Abstract

Various methods and systems are provided for patterned multi-slice excitation (PME) magnetic resonance image (MRI). In one example, a method for imaging a patient according to a PME MRI slice acquisition protocol includes, during a first pulse interval, applying a first radiofrequency (RF) pulse together with a first slice selection gradient to excite a first slice and a second slice, the second slice following the first slice in the slice acquisition protocol, and acquiring MR signals of only the first slice; and during a second pulse interval following the first pulse interval, applying a second RF pulse together with a second slice selection gradient to excite the second slice and a third slice, the third slice following the second slice in the slice acquisition protocol, and acquiring MR signals of only the second slice.

IPC Classes  ?

• G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography

Abstract

Enzymatic radiosyntheses of deoxy-[18F]fluorocellobiose and deoxy-[18F]fluorocellotriose are disclosed. Deoxy-[18F]fluorocellobiose is synthesized in 1-2 hours from (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, and a cellobiose phosphorylase (CBP), or (ii) deoxy-[18F]fluoroglucose-1-phosphate, glucose, and a CBP. Deoxy-[18F]fluorocellotriose is synthesized in 1-2 hours from (i) deoxy-[18F]fluoroglucose, glucose-1-phosphate, CBP, and a CBP variant, (ii) deoxy-[18F]fluorocellobiose, glucose-1-phosphate, and a CBP variant, or (iii) deoxy-[18F]fluoroglucose-1-phosphate, cellobiose, and a CBP variant.

IPC Classes  ?

• C12P 19/12 - Disaccharides
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• A61K 51/04 - Organic compounds
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07H 3/04 - Disaccharides
• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Abstract

Disclosed are allosteric inhibitors of the Plk1 Polo Box Doamin (PBD), which are useful in treating cancers by inducing mitotic block of the cancer cells. Examples of such inhibitors include compounds of formula (I) and (II), as well as pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined. Also disclosed are pharmaceutical compositions containing a compound or salt thereof and a method of treating cancer in an animal by administering to the animal an effective amount of the compound or the pharmaceutical composition.

IPC Classes  ?

• C07D 491/14 - Ortho-condensed systems
• C07D 495/14 - Ortho-condensed systems
• C07D 209/40 - Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
• C07D 215/38 - Nitrogen atoms
• C07D 215/50 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
• C07D 231/38 - Nitrogen atoms
• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 333/78 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 495/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are isolated or purified T cell receptors (TCRs) having antigenic specificity for human p53Y220Cor human p53R175H. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure provides engineered mammalian dendritic cells that express exogenous Major Histocompatibility Complex (MHC) class II alleles. Methods for using the engineered mammalian dendritic cells of the present disclosure for semi-allogeneic and autologous dendritic cell-based immunotherapy in a subject are also provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The invention provides a fluorinated compound of Formula (I): a deuterated or tritiated variant thereof, or a pharmaceutically acceptable salt thereof, wherein at least one C–H bond on the compound of Formula (I) is replaced with a C–F bond or a C–18F bond. The invention further provides compositions comprising the fluorinated compound, a deuterated or tritiated variant thereof, or a pharmaceutically acceptable salt thereof, and methods of using the fluorinated compound, a deuterated or tritiated variant thereof, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 235/06 - BenzimidazolesHydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• C07D 235/10 - Radicals substituted by halogen atoms or nitro radicals
• C07D 235/12 - Radicals substituted by oxygen atoms
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/36 - Opioid-abuse
• A61P 23/00 - Anaesthetics
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Abstract

Methods are disclosed for treating or reducing the risk of developing age-related macular degeneration (AMD) in a subject. These methods can include selecting a subject having, or at risk of developing, the AMD and administering to the subject an effective amount of an agent that inhibits HERV-K. An agent that inhibits HERV-K includes, but is not limited to, an antibody, an inhibitory RNA molecule, an anti-retroviral agent, a CRISPR/Cas13 system targeting HERV-K, as well as angiogenin. A CRISPR/Cas13 system targeting HERV-K is also provided. These methods also can include selecting a subject having, or at risk of developing, the AMD and administering to the subject an effective amount of an agent that increases ANG activity.

IPC Classes  ?

• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61P 27/02 - Ophthalmic agents

Abstract

Disclosed are pharmaceutical formulations comprising a compound of formula (I): Disclosed are pharmaceutical formulations comprising a compound of formula (I): Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The disclosure provides a method of treating or preventing a bacterial infection in a subject comprising administering a therapeutically effective amount of a combination of a bacterial type IIA topoisomerase inhibitor, or a pharmaceutically acceptable salt thereof and a compound Formula I, or a pharmaceutically acceptable salt thereof, to the subject, where the compound of Formula I is (Formula (I)) where the variables, e.g. Y1, Y2, and R1-R4, are described herein. The bacterial type IIA topoisomerase inhibitor can be a quinolone antibiotic such as ciprofloxacin. The disclosure provides a method of treating or preventing a bacterial infection in a subject comprising administering a therapeutically effective amount of a combination of a bacterial type IIA topoisomerase inhibitor, or a pharmaceutically acceptable salt thereof and a compound Formula I, or a pharmaceutically acceptable salt thereof, to the subject, where the compound of Formula I is (Formula (I)) where the variables, e.g. Y1, Y2, and R1-R4, are described herein. The bacterial type IIA topoisomerase inhibitor can be a quinolone antibiotic such as ciprofloxacin.

IPC Classes  ?

• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents

Abstract

Rapid, sensitive, and low-cost methods for the detection of hepatitis C virus (HCV) RNA in biological samples using reverse transcription loop-mediated isothermal amplification (RT-LAMP) reactions and rationally designed primers are described. The RT-LAMP primers can amplify nucleic acid from all HCV genotypes. The methods, primers and kits of the disclosure are suitable for point-of-care diagnostics. Efficient methods for isolation of HCV RNA from whole blood are also described.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention provides devices and methods for electroporation. Embodiments of the invention provide an electroporation device, the device having: a microfluidic channel with a fluid inlet and a fluid outlet; and a pair of interdigitated electrodes formed within said channel, wherein said electrodes are coated with PEDOT:PSS on a contact surface which is in contact with fluid in the channel. Other embodiments of the invention provide a method of performing electroporation on cells in a sample, the method including the steps of: introducing the sample into a chamber having a pair of electrodes each having a coating of PEDOT:PSS on a contact surface which is in contact with the sample; and applying oscillating stimulation voltage signals to the sample using the electrodes, wherein the stimulation voltage signals are applied so as to stimulate electroporation in the cells.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

in vitroin vivoin vivo. In some aspects, disclosed are methods of producing these non-natural human chondrocytes. In further aspects, disclosed are methods of using these non-natural human chondrocytes, such as for promoting cartilage growth and/or repair.

IPC Classes  ?

• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The present disclosure describes the grafting of epitope residues from human PCSK9 to non-human PCSK9 or PCSK9 structural homologs and elimination of 9-mers oligopeptides that are found in human protein to reduce self-targeting response. Anti-genicity of the epitope-scaffold constructs was demonstrated toward anti-human PCSK9 antibodies. similar to wild type human PCSK9. It was shown that disclosed PCSK9 immunogens could significantly reduce LDL and cholesterol levels in immunized mice.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 3/06 - Antihyperlipidemics
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

3333R antagonism/partial agonism. The novel compounds are useful in the treatment of pain and substance use disorders.

IPC Classes  ?

• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• C07D 311/96 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The disclosure provides systems and a protocol for monitoring the health of a fetus and a mother during pregnancy. A wearable device utilizing near-infrared spectroscopy (NIRS) is disclosed for monitoring a number of parameters associated with placental tissue, the fetus, and/or the mother. The device includes one or more light sources and one or more photodetectors, each photodetector separated from a particular light source by a corresponding separation distance. The device further includes a processor configured to collect data based on intensity information collected by the plurality of photodetectors responsive to activation of one or more of the plurality of light sources. The data is used to estimate an oxygen saturation level for a layer of placental tissue in a uterus of a mother, or maternal physiological signals including respiratory functions, cardiac functions, oxygenation levels, or fetal cardiac functions.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/1464 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters specially adapted for foetal tissue
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

The present invention pertains to a composition for preventing or treating systemic capillary leak syndrome (SCLTimeS), the composition containing a Tie2 receptor activating agent as an active ingredient.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Recombinant adeno-associated virus (AAV) vectors encoding a modified VP1 protein lacking an immunodominant T cell epitope, as well as AAV vector particles containing the modified VP1 protein, are described. Use of the recombinant AAV vectors and vector particles as improved gene therapy vectors with reduced immunogenicity is also described. Isolated VP1 peptides containing an immunodominant T cell epitope, and use thereof, is further described.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided herein are hypoallergenic mutant Ara h proteins, including Ara h 2 and Ara h 6, and uses thereof in treating allergic or anaphylactic responses to peanut allergens, immunotherapy and diagnostics.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A61K 39/35 - Allergens
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 37/08 - Antiallergic agents

Abstract

A method of processing a sample plate containing a plurality of samples includes aspirating simultaneously, from the sample plate, a first sample droplet from a first sample of the plurality of samples with a first pipette and a second sample droplet from a second sample of the plurality of samples with a second pipette. The sample plate also includes dispensing sequentially, from the first pipette and the second pipette, the first sample drop and the second sample drop into an open port interface (OPI).

IPC Classes  ?

• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices

Abstract

Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.

IPC Classes  ?

• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells

Abstract

Modified Epstein-Barr virus (EBV) glycoprotein 42 (gp42) polypeptides that retain immunogenicity, but are impaired for binding HLA class II molecules are described. Use of the modified gp42 polypeptides in immunogenic compositions, such as in self-assembling protein nanoparticle compositions, is also described. Methods for screening B cells that express gp42-specific monoclonal antibodies using the modified gp42 polypeptides as a probe, are also described.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses

Abstract

Systems and methods for a convolutional neural network classifier to detect retinal vasculitis in color fundus photographs of patients with uveitis using a feature extraction and classification operations are disclosed herein.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 40/14 - Vascular patterns
• G06V 40/18 - Eye characteristics, e.g. of the iris

Abstract

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

Provided herein are methods and immune biomarkers that identify progression and treatment options for multiple sclerosis (MS). Also provided are materials and methods for the prognosis, staging, and monitoring of MS in a sample and include methods of determining a subject as being at risk of developing MS. The methods include detecting at least one biomarker, such as CXCL13, CXCL10, CD27, NEFL, CCL4, and/or CCL3 in cerebrospinal fluid (CSF) in the subject; and administering a pharmaceutically effective amount of a treatment (e.g., tolebrutinib and potentially one or more additional therapies, such as an anti-CD20 therapy) to the subject.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided herein are varicella-zoster virus vaccine, human papillomavirus vaccine, and Rabies vaccine antigens, compositions thereof, and uses thereof in cancer immunotherapy and cancer treatment.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a CD22 amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Disclosed is a compound of formula (I) or salt thereof: Formula (I) for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.

IPC Classes  ?

• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 31/47 - QuinolinesIsoquinolines

Abstract

Disclosed herein are assays for detecting interaction of a target of interest (TOI) with a compound. Specifically, the disclosed assays are based on the idea that compound-induced change in the structural conformation ensemble distribution environment of a label attached to the TOI may be used to detect interaction of the compound with a TOI. The label may be part of a complementary reporter system that uses a substrate to produce a fluorescent or chemiluminescent signal. Alternatively, the label may be detected directly by fluorescence.

IPC Classes  ?

• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase
• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

An intubation system for directing water to and from an aquatic specimen during the visual observation thereof can include an intubation chamber that facilitates the guided direction of an inflow tube and a plurality of outflow tubes to the specimen. The intubation chamber can be manufactured by an additive manufacturing process to include various inflow and outflow tube channels in a relative complex geometry. An inflow channel guide may be included and can be fitted to the intubation chamber to guide the inflow tube to the intended location of the head of the specimen. The intubation system may also include a brace plate having a chamber opening for the correct positioning of the intubation chamber with respect to the system. A drug delivery system can include a syringe pump and a multiport junction to fluidly introduce a liquid drug to the inflow tube upstream of the intubation chamber.

IPC Classes  ?

• A01K 61/10 - Culture of aquatic animals of fish

Abstract

A compound, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, having a structure of Formula (I) wherein R1, R2, X and a are defined in the claims.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 31/12 - Antivirals
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

MRI visible reporter systems comprising ZIP14 and/or ZIP8 and methods of use.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• A61K 33/30 - ZincCompounds thereof

Abstract

Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 14/21 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Pseudomonadaceae (F)
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are perfluorinated SABRE catalysts comprising a d-block element and a perfluorinated ligand, wherein the perfluorinated ligand is of Formula (I): [Lm-(NHC)—(Y—Z)q] or a salt thereof. Also disclosed is a method of preparing a hyperpolarized substrate comprising a ½ spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration to an animal. Further disclosed is a method of imaging a tissue of an animal suspected of having a disease or condition.

IPC Classes  ?

• B01J 31/22 - Organic complexes
• C07C 51/487 - SeparationPurificationStabilisationUse of additives by treatment giving rise to chemical modification

Abstract

Monoclonal antibodies that bind Sudan virus (SUDV) and/or Ebola virus (EBOV) glycoprotein (GP) with nanomolar affinity are described. The monoclonal antibodies were developed by single-cell sorting of B cells obtained from non-human primate and human subjects previously immunized with Ebola (Zaire) virus (EBOV) and Sudan virus (SUDV) glycoprotein. Use of the monoclonal antibodies for treating, inhibiting, and detecting infection by SUDV and EBOV is also described.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Monoclonal antibodies and bispecific monoclonal antibodies that bind Sudan virus (SUDV) and/or Ebola virus (EBOV) glycoprotein (GP) with nanomolar affinity are described. The monoclonal antibodies were developed by single-cell sorting of B cells obtained from non-human primate and human subjects previously immunized with Ebola (Zaire) virus (EBOV) and Sudan virus (SUDV) glycoprotein. Use of the monoclonal antibodies and bispecific antibodies for treating, inhibiting, and detecting infection by SUDV and EBOV is also described.

IPC Classes  ?

• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Ex vivo analysis can be performed by mounting a portion of live tissue resected from a patient on a sample platform. Using the sample platform, the resected tissue portion can be positioned within a perfusion chamber. Perfusate is flowed through the perfusion chamber and into contact with the resected tissue portion such that diffusion of oxygen occurs between the perfusate and the resected tissue portion. During the flowing, the resected tissue portion maintains a competent immune system. Drugs can be added to the perfusate flow to ascertain the effect on the tissue. The sample platform is designed to be removable from the perfusion chamber for analysis of the tissue by imaging or other investigation techniques, for experimental treatment, or for any other purpose. After removal, the sample platform can be returned to the perfusion chamber for continued viability of the tissue.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

StO2StO22 StO2 2 2 parameter can be calculated for each distinct source-detector pair of an optical device, reducing the cost and complexity of the device and enabling further miniaturization.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition

Abstract

Plasmodium Plasmodium spp P48/45 protein. Such modified proteins retain an epitope that elicits neutralizing antibodies against the P48/45 protein. Also disclosed are nucleic acid molecules encoding the modified proteins, nanoparticles displaying the modified protein, as well as methods of using the modified proteins and nanoparticles.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• C07K 14/445 - Plasmodium
• A61P 33/00 - Antiparasitic agents

Abstract

nn-L-P (I), wherein T is a thyclotide unit of the formula:, wherein the thyclotide units are optionally intercepted by segments of polypeptide which can be the same as or different from P, n is about 5 to about 25, L is a linker, P is a polypeptide, and B is a nucleobase or a heterocyclyl moiety. Also disclosed are pharmaceutical compositions and methods of treating diseases such as cancers by administering an effective amount of a thyclotide-peptide conjugate.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides materials and methods for detecting the presence of nucleic acids, including RNA and/or DNA, from single cells. The present disclosure describes methods and workflows to detect, sort, sequence nucleic acids from rare cell types using various encapsulation, reverse transcription, amplification and detection techniques that allows linking of a single cell's genotype and phenotype.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C08J 3/075 - Macromolecular gels
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

in vitroin vivoin vivo methods of specifically detecting or/and measuring the level of ASCT1, and to the use of said polypeptides in diagnosis and therapy.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus

Abstract

Provided herein are compositions and methods for treating retinal degeneration, such as an inherited retinal degeneration. In some examples, the compositions include a pigment epithelium-derived factor (PEDF) protein or a peptide thereof. Compositions including a PEDF 17mer[H105A] peptide in an eye drop formulation or an adeno-associated virus vector including a nucleic acid encoding a PEDF protein or PEDF 17mer[H105A] peptide are provided. Methods for treating retinal degeneration include administering a provided eyedrop formulation or adeno-associated virus vector to an eye of a subject with retinal degeneration.

IPC Classes  ?

• A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• A61P 27/02 - Ophthalmic agents
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Disclosed herein are isolated antibodies that bind one or more species of alphaviruses. In certain aspects, the disclosed antibodies bind and neutralize three or more species of alphaviruses. Also disclosed are methods of using the disclosed antibodies to prevent infection of a cell with an alpha virus, to protect an individual from alphavirus infection, and to treat an individual for an alphavirus infection.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Peptides, platforms and methods for detecting antibody responses to filovirus infections, detecting antibody responses to EBOV infection, and detecting antibody responses to vaccination by EBOV vesicular stomatitis virus-based vaccine.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

Methods and bisacridine compositions for inhibiting topoisomerase III beta (TOP3B) and conferring antiviral and/or anti-cancer activity are disclosed.

IPC Classes  ?

• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• C07D 219/12 - Aminoalkyl-amino radicals attached in position 9

Abstract

The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

Methods and polymethine bridge-containing cyanine compositions for inhibiting topoisomerase III beta (TOP3B), RNA-dependent RNA polymerases, and RNA-dependent DNA polymerases and conferring antiviral and/or anti-cancer activity are disclosed.

IPC Classes  ?

• C09B 23/00 - Methine or polymethine dyes, e.g. cyanine dyes
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 51/04 - Organic compounds
• A61P 35/00 - Antineoplastic agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to influenza virus immunisation using at least one influenza HA stem polypeptide in conjunction with squalene emulsion adjuvants, and to related aspects.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/04 - Immunostimulants

Abstract

An aspect of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors

Abstract

A myotomy catheter for performing longitudinal myocardial incisions is provided. In one example, a catheter-based heart incision apparatus comprises an anchor stabilization and orientation catheter system with at least one anchor element and an incision catheter including a lacerator configured to move along an incision trajectory oriented by the at least one anchor element.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61B 18/14 - Probes or electrodes therefor
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 17/34 - TrocarsPuncturing needles
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

The disclosure provides engineered nucleotide sequences, vectors, and pharmaceutical compositions that can be used in methods for treating a disease or disorder with an associated haploinsufficiency and/or cancer.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters